EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort

Clément Grosnon iD, Lauren Seknazi, Djamel Ghebriou, Anne Sabaila, David Buob, Mariana Nedelcu, Marjolaine Le Gac, Mathieu Jamelot, Coralie Prebet, Jean-Pierre Lotz, Joseph Gligorov iD, Marc-Antoine Benderra iD

Cancer Medicine · 2025-11 · 14 (22)

DOI: 10.1002/cam4.71386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 20.11.2025. Verfasst von Clément Grosnon und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Oncotype DX Breast Recurrence Score test was designed for HR+, HER2− early breast cancer (eBC) to assist in the decision‐making process for de‐escalating adjuvant chemotherapy (CT). Its validity and utility have been demonstrated prospectively across multiple studies, though data on older patients remain limited.

Methods

This prospective cohort study included patients over 70 years with eBC treated between 2018 and 2023 at Tenon Hospital, Paris, France. Characteristics of populations eligible for the test and those with RS ≤ or > 25 were collected, along with oncogeriatric assessment and treatments; statistical analysis was performed for IDFS and OS.

Results

Of the 365 patients > 70 years, mean age was 77.6 years (range 70–96), with 84.4% diagnosed with HR+/HER2− eBC. Oncotype DX testing was performed in 85 patients (27.9% of HR+/HER2− eBC), revealing a Recurrence Score (RS) result > 25 in 14 patients (15%). The RS > 25 group had more grade 3 tumors, more pT2 tumors, and a higher Ki67 > 20%. In the RS > 25 group, 9 patients (64%) had oncogeriatric consultations, and 7 (50%) started the recommended adjuvant CT. Four patients received taxane‐cyclophosphamide (TC) and 3 adriamycin‐cyclophosphamide‐taxane (AC‐T), with 2 discontinuing due to taxane‐induced neuropathy. Median IDFS was significantly lower in the RS > 25 group ( p = 0.0023), with 4 of 5 recurrences occurring in patients who did not receive adjuvant CT. OS showed no significant difference by RS group ( p = 0.87).

Conclusion

This observational study highlights that the Oncotype DX test supports therapeutic de‐escalation in patients with RS ≤ 25 and serves as a prognostic marker. Oncogeriatric evaluations are essential to guide adjuvant treatments in older breast cancer patients prior to using genomic signatures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplasm Recurrence, LocalBiomarkers, TumorHumansFemaleAgedAged, 80 and overProspective StudiesChemotherapy, AdjuvantErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsReceptors, EstrogenPrognosisGene Expression ProfilingCyclophosphamide

Stichwörter der Autor:innen

Oncotype DXadjuvant chemotherapybreast cancerolder patients

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorReceptors, EstrogenCyclophosphamideERBB2 protein, human

Autor:innen und Institutionen

  • Medical Oncology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France.
  • Gynaecology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France.
  • Anatomopathology Department, Institut Universitaire de Cancérologie AP-HP Sorbonne Université, Tenon Hospital, Paris, France.

ORCID-Profile: Clément Grosnon, Joseph Gligorov, Marc-Antoine Benderra

Zitieren

APA

Grosnon, C., Seknazi, L., Ghebriou, D., Sabaila, A., Buob, D., Nedelcu, M., Le Gac, M., Jamelot, M., Prebet, C., Lotz, J. P., Gligorov, J., & Benderra, M. A. (2025). Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort. Cancer Medicine, 14(22). https://doi.org/10.1002/cam4.71386

Vancouver

Grosnon C, Seknazi L, Ghebriou D, Sabaila A, Buob D, Nedelcu M, et al. Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort. Cancer Medicine. 2025;14(22). doi:10.1002/cam4.71386

BibTeX
@article{Grosnon2025,
  author = {Grosnon, Clément and Seknazi, Lauren and Ghebriou, Djamel and Sabaila, Anne and Buob, David and Nedelcu, Mariana and Le Gac, Marjolaine and Jamelot, Mathieu and Prebet, Coralie and Lotz, Jean-Pierre and Gligorov, Joseph and Benderra, Marc-Antoine},
  title = {Oncotype Dx Breast Cancer Assay in Older Patients: A Real Life Cohort},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {22},
  doi = {10.1002/cam4.71386}
}
Kostenlos starten →